BG
IRWD icon

Bellevue Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bellevue Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-91,341
Closed -$793K – 143
2018
Q4 		$793K Sell
91,341
-3,463
-4% -$39.7K 0.05% 122
2018
Q3 		$1.47M Buy
+94,804
New +$1.5M 0.09% 113

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Bellevue Group's IRWD Position: Q1 2019 in Review

Bellevue Group sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2019, closing a stake of 91,341 shares — an estimated $793K sold.

Bellevue Group first reported a position in IRWD in Q3 2018 and held it in 2 quarters. The position peaked at $1.47M in Q3 2018. 156 funds tracked by Wall St. Rank hold IRWD as of Q1 2019.

  • Bellevue Group reported no remaining Ironwood Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Bellevue Group sold 91,341 Ironwood Pharmaceuticals shares in Q1 2019, an estimated $793K.
  • Bellevue Group first reported a position in Ironwood Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Bellevue Group's Ironwood Pharmaceuticals position peaked at $1.47M in Q3 2018.
  • 156 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2019.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.